Structures by: Desper J.


Structures by: Desper J.

Results: 455


#NameUnit Cell
1502292K-75 2-chloro-3-(4-methoxyphenyl)-4-aminoquinazolinium chloride
Organic letters (2011) 13, 14 3718-3721
a=10.8130(7)
b=6.7024(4)
c=20.2381(11)
α= 90.00
β= 92.626(4)
γ= 90.00
V = 1465.18(15)
1505170{1[(1-benzimidazolyl)methyl]-4[(1-pyrazolyl)methyl]benzene}2, succinic acid
Molecular Pharmaceutics (2007) 4, 3 317
a=5.6367(4)
b=32.910(3)
c=9.4476(7)
α= 90.00
β= 102.342(6)
γ= 90.00
V = 1712.1(2)
1505172MF-34-33 3-(4-pyridyl)pyrazole, (Me5-PhCOOH)2
Molecular Pharmaceutics (2007) 4, 3 317
a=8.8864(5)
b=11.9875(7)
c=13.7015(8)
α= 99.3800(10)
β= 93.1910(10)
γ= 107.5560(10)
V = 1364.42(14)
15051731-[(1-benzimidazolyl)methyl]-3-[(1-pyrazolyl)methyl]benzene (3,5-diNO2PhCOOH)2
Molecular Pharmaceutics (2007) 4, 3 317
a=9.7657(6)
b=11.7691(7)
c=14.0803(9)
α= 86.2270(10)
β= 74.1630(10)
γ= 86.2020(10)
V = 1551.53(17)
1506032hexyl bromo calixarene, acetonitrile
Organic letters (2006) 8, 12 2607-2610
a=10.7767(7)
b=11.6740(7)
c=20.8192(13)
α= 80.392(4)
β= 86.826(4)
γ= 76.503(3)
V = 2510.8(3)
1506033hexyl bromo calixarene, dichloromethane
Organic letters (2006) 8, 12 2607-2610
a=10.4432(15)
b=15.049(2)
c=16.320(2)
α= 90.00
β= 97.977(3)
γ= 90.00
V = 2540.0(6)
1506034NS 1 pentyl calixarene + acetonitrile
Organic letters (2006) 8, 12 2607-2610
a=18.3708(7)
b=18.3708(7)
c=19.8745(15)
α= 90.00
β= 90.00
γ= 90.00
V = 6707.4(6)
1506035NS 14 pentyl calixarene (+ octanedioic acid)
Organic letters (2006) 8, 12 2607-2610
a=23.3560(16)
b=22.1519(16)
c=25.5165(16)
α= 90.00
β= 94.302(4)
γ= 90.00
V = 13164.5(16)
1513817HG82D
Organic letters (2014) 16, 5 1494-1497
a=13.1171(8)
b=13.5030(8)
c=22.5774(13)
α= 95.970(3)
β= 100.719(3)
γ= 115.780(3)
V = 3459.9(4)
1513818II-VKN-91
Organic letters (2014) 16, 5 1494-1497
a=11.0318(6)
b=6.8167(3)
c=21.8563(11)
α= 90.00
β= 94.287(2)
γ= 90.00
V = 1639.01(14)
20151314-(dimethylamino)benzoic acid
Acta Crystallographica Section C (2005) 61, 12 o702-o704
a=9.6507(11)
b=9.8918(11)
c=10.0082(10)
α= 76.118(6)
β= 67.655(7)
γ= 69.334(9)
V = 820.61(16)
2235942Diaqua[(1R,2S,4R,8R,9S,11R)-2,9- dimethyl-1,4,8,11-tetraazacyclotetradecane]nickel(II) dichloride dihydrate
Acta Crystallographica Section E (2012) 68, 8 m1111-m1112
a=9.7309(8)
b=14.0994(11)
c=14.6000(11)
α= 90.00
β= 90.00
γ= 90.00
V = 2003.1(3)
41036822K-8-100-dp
Journal of the American Chemical Society (2010) 132, 17635-17641
a=11.8671(16)
b=14.0629(18)
c=14.0671(17)
α= 71.370(6)
β= 81.391(8)
γ= 87.499(10)
V = 2199.5(5)
4103683(C88H48O12)(C2H5O)
Journal of the American Chemical Society (2010) 132, 17635-17641
a=33.0333(17)
b=33.0333(17)
c=33.0333(17)
α= 90.00
β= 90.00
γ= 90.00
V = 36046(3)
4105415SF22 4-pyridyl-CONH-(CH2)6)-NHCO-(4-pyridyl), succinic acid CHUNKS
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1754(4)
b=10.9294(8)
c=10.9423(8)
α= 118.826(4)
β= 91.381(5)
γ= 99.872(4)
V = 530.11(7)
4105416SF 2 4-pyridyl-CONH-(CH2)6-NHCO-4-pyridyl, HOOC-(CH2)4-COOH
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1412(4)
b=5.2394(4)
c=21.3961(17)
α= 95.094(5)
β= 95.603(4)
γ= 91.076(5)
V = 571.10(8)
4105417SF21 N,N-(isonicotinyl)hexanediamine, octanedioic acid
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1392(5)
b=5.2412(5)
c=23.145(2)
α= 94.050(3)
β= 95.222(2)
γ= 91.277(2)
V = 619.03(10)
4105418SF3 (4-pyridyl)-CONH-(CH2)6-NHCO-(4-pyridyl), HOOC-(CH2)8-COOH
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1506(4)
b=5.2481(4)
c=24.5206(16)
α= 89.647(4)
β= 87.252(4)
γ= 88.505(5)
V = 661.82(8)
4105419SF5 (4-pyridyl)-CONH-(CH2)6-NHCO-(4-pyridyl), HOOC-(CH2)10-COOH
Journal of the American Chemical Society (2009) 131, 17048-17049
a=5.1519(4)
b=5.2778(5)
c=26.148(3)
α= 86.023(6)
β= 89.386(6)
γ= 88.496(6)
V = 709.00(12)
4115154N-cinnamoyl alanine amide
Journal of the American Chemical Society (2002) 124, 11315-11323
a=13.514(6)
b=4.7974(19)
c=21.238(10)
α= 90.00
β= 97.137(7)
γ= 90.00
V = 1366.2(10)
4115155fumaric acid bis(leucine methyl ester) amide
Journal of the American Chemical Society (2002) 124, 11315-11323
a=14.440(5)
b=4.852(2)
c=27.377(11)
α= 90.00
β= 90.00
γ= 90.00
V = 1918.1(13)
4302060(1,3-Ph2acac)Co(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9670(6)
b=11.2006(7)
c=15.3238(9)
α= 75.533(3)
β= 80.377(4)
γ= 79.221(4)
V = 1452.18(16)
4302061(1,3-Ph2acac)Ni(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9948(19)
b=11.185(2)
c=15.409(3)
α= 75.737(9)
β= 79.844(13)
γ= 78.971(16)
V = 1461.1(5)
4302062Cu{[4-(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide}2(F6-acac)2 (CH3CN)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.349(3)
b=10.688(3)
c=12.680(3)
α= 98.217(6)
β= 110.457(5)
γ= 104.465(5)
V = 1230.8(6)
4302063{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
Inorganic Chemistry (2009) 48, 4052-4061
a=9.7354(11)
b=11.1497(12)
c=23.870(3)
α= 90.00
β= 96.985(2)
γ= 90.00
V = 2571.8(5)
4302064bis{4-[(pyrazol-1-yl)methyl]benzamide} (Ph2-acac)2 Ni(II) bis{ethanol} (Ph2-acac)2 Ni(II)
Inorganic Chemistry (2009) 48, 4052-4061
a=9.0170(6)
b=12.3493(8)
c=17.6357(12)
α= 86.3190(10)
β= 78.0890(10)
γ= 72.2410(10)
V = 1830.0(2)
4302065{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.0325(10)
b=15.1765(15)
c=16.6440(16)
α= 90.00
β= 99.957(2)
γ= 90.00
V = 2496.0(4)
4302066527 4-[(2-phenylimidazol-1-yl)methyl]benzamide, mu-Cu2(F-PhCOO)4
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9536(9)
b=11.2155(8)
c=14.9765(12)
α= 77.570(6)
β= 78.159(4)
γ= 74.526(5)
V = 1710.1(2)
4302067528 3-[(2-phenylimidazol-1-yl)methyl]benzamide, Cu2(2-FC6H4COO)4 (CH3CN)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9819(16)
b=11.2072(15)
c=14.926(2)
α= 99.042(8)
β= 91.419(6)
γ= 116.183(7)
V = 1618.8(4)
4302068BS-2-11e mu(o-FPhCOO)4 Cu2[4-imidazolylmethylbenzamide]2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.8218(9)
b=19.4000(14)
c=12.0541(8)
α= 90.00
β= 108.346(4)
γ= 90.00
V = 2402.0(3)
4302069BS-3-44-2A 4-[(pyrazol-1-yl)methyl]PhCONH2, mu4-(AcO)Cu CH3CN
Inorganic Chemistry (2009) 48, 4052-4061
a=7.5896(5)
b=10.0990(7)
c=13.3959(8)
α= 68.531(4)
β= 82.310(3)
γ= 72.114(3)
V = 909.07(11)
4302070mu(OAc)4 Cu2 {3-[(pyrazol-1-yl)methyl]benzamide}2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.0173(4)
b=10.1615(5)
c=11.4846(6)
α= 110.1640(10)
β= 109.1250(10)
γ= 90.5040(10)
V = 821.95(7)
4304510Al-4-26 Cu(OH)2
Inorganic Chemistry (2008) 47, 1120-1126
a=7.5321(7)
b=16.0522(14)
c=17.4225(15)
α= 90.00
β= 92.7830(10)
γ= 90.00
V = 2104.0(3)
4304511trans-1,2-diaminocylohexane monoimine
Inorganic Chemistry (2008) 47, 1120-1126
a=6.1675(8)
b=11.9167(15)
c=18.033(2)
α= 90.00
β= 90.00
γ= 90.00
V = 1325.4(3)
4304512AL-608 (AL-4-26 Fe)
Inorganic Chemistry (2008) 47, 1120-1126
a=8.8032(4)
b=12.5533(6)
c=12.3334(6)
α= 90.00
β= 95.159(2)
γ= 90.00
V = 1357.43(11)
4304513AL-4-26 / CoI2-R
Inorganic Chemistry (2008) 47, 1120-1126
a=8.8100(8)
b=12.4866(12)
c=12.3007(12)
α= 90.00
β= 94.572(4)
γ= 90.00
V = 1348.9(2)
4304514AL-4-26/NiI2-R
Inorganic Chemistry (2008) 47, 1120-1126
a=8.8514(6)
b=12.5256(9)
c=12.1886(9)
α= 90.00
β= 94.5630(10)
γ= 90.00
V = 1347.06(17)
4304515AL-4-26/ZnCl2-R
Inorganic Chemistry (2008) 47, 1120-1126
a=8.7802(7)
b=12.5067(10)
c=12.3400(10)
α= 90.00
β= 94.8560(10)
γ= 90.00
V = 1350.21(19)
4309158(F6-acac)2[3-(2-amino-4-methoxypyrimidin-6-yl)pyridine]2Cu(II) (CHCl3)2
Inorganic Chemistry (2005) 44, 4983-4991
a=10.4149(6)
b=12.1682(7)
c=18.2488(10)
α= 105.6980(10)
β= 105.8970(10)
γ= 93.1160(10)
V = 2120.6(2)
4309159bis(1,3-Ph2propanedionato)-bis[3(2-amino-4-methoxypyrimidin-6-yl) pyridine]Co(II)
Inorganic Chemistry (2005) 44, 4983-4991
a=9.3368(7)
b=10.3686(8)
c=11.0609(8)
α= 85.536(2)
β= 79.677(2)
γ= 83.026(2)
V = 1043.95(14)
4309160bis(F6-acac)bis[3-(2-amino-4-methylpyrimidin-6-yl)pyridine]copper(II) 1,2-dichloroethane
Inorganic Chemistry (2005) 44, 4983-4991
a=8.2843(4)
b=10.8750(5)
c=11.7573(6)
α= 113.0810(10)
β= 94.4120(10)
γ= 103.8330(10)
V = 928.76(8)
43091611-(2-amino-4-methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne, Cu(F6-acac)2
Inorganic Chemistry (2005) 44, 4983-4991
a=9.6243(11)
b=10.4481(12)
c=13.8822(15)
α= 85.905(2)
β= 86.300(2)
γ= 74.690(2)
V = 1341.4(3)
4309162[1-(2-amino-4-Methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne]2, Co(PhCOCCOPh)2
Inorganic Chemistry (2005) 44, 4983-4991
a=10.5076(5)
b=10.7568(6)
c=11.9544(6)
α= 68.9160(10)
β= 82.6200(10)
γ= 69.1900(10)
V = 1178.48(11)
43091631-(2-amino-4-Methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne, Ni(Ph2acac)2
Inorganic Chemistry (2005) 44, 4983-4991
a=10.4666(7)
b=10.6669(7)
c=11.9828(8)
α= 68.678(4)
β= 82.626(4)
γ= 69.230(3)
V = 1165.27(14)
4501217PC-4-10e (2-aminopyrazine)2, 1,4-diiodotetrafluorobenzene
Crystal Growth & Design (2011) 11, 12 5333
a=7.9013(6)
b=5.6116(4)
c=20.1258(16)
α= 90.00
β= 101.260(4)
γ= 90.00
V = 875.18(12)
45012184-11e 2-amino-5-bromopyrazine, 1,4-diiodotetrafluorobenzene
Crystal Growth & Design (2011) 11, 12 5333
a=5.6316(6)
b=8.1219(9)
c=21.226(2)
α= 90.00
β= 93.035(4)
γ= 90.00
V = 969.50(17)
45012194-12e (3-amino-2,6-dibromopyrazine)2, 1,4-diiodotetrafluorobenzene
Crystal Growth & Design (2011) 11, 12 5333
a=5.6428(4)
b=9.7705(7)
c=10.4014(7)
α= 100.821(3)
β= 103.743(3)
γ= 93.752(3)
V = 543.49(7)
4504361NS10b 2-amino-4-(4-pyridyl)-6-methylpyrimidine
Crystal Growth & Design (2007) 7, 11 2324
a=12.7944(9)
b=12.9712(9)
c=23.1035(15)
α= 90.00
β= 90.246(4)
γ= 90.00
V = 3834.2(5)
45043631-(2-amino-4-methylpyrimidin-6-yl)-2-(3-methoxypyridin-5-yl)ethyne, (CH2Cl2)0.5
Crystal Growth & Design (2007) 7, 11 2324
a=7.2432(8)
b=7.7893(8)
c=12.6950(13)
α= 107.292(2)
β= 91.059(2)
γ= 98.566(2)
V = 674.75(12)
4504640[N-(2-pyridyl) acetamide]2, fumaric acid
Crystal Growth & Design (2006) 6, 2 474
a=4.8875(5)
b=8.4817(8)
c=11.4723(11)
α= 110.375(2)
β= 91.000(2)
γ= 96.451(2)
V = 442.18(7)
4504641[N-(2-pyridyl)acetamide]2, succinic acid
Crystal Growth & Design (2006) 6, 2 474
a=9.1172(8)
b=9.2969(8)
c=10.6430(9)
α= 90.00
β= 92.694(2)
γ= 90.00
V = 901.12(13)
4504645[N-(2-pyridyl)acetamide]2, nonanedioic acid
Crystal Growth & Design (2006) 6, 2 474
a=16.563(3)
b=8.5279(12)
c=18.464(3)
α= 90.00
β= 114.909(9)
γ= 90.00
V = 2365.4(7)
4504646[N-(2-pyridyl)acetamide]2, decanedioic acid
Crystal Growth & Design (2006) 6, 2 474
a=5.3767(4)
b=6.5416(4)
c=17.0662(12)
α= 92.8090(10)
β= 90.2470(10)
γ= 101.3140(10)
V = 587.82(7)
4504647N-(3-pyridyl)acetamide, 5-nitroisophthalic acid
Crystal Growth & Design (2006) 6, 2 474
a=19.5362(14)
b=9.3631(7)
c=12.7665(10)
α= 90.00
β= 113.382(4)
γ= 90.00
V = 2143.5(3)
4504813(4-bromo-phenylacetonitrile oxime)2, 1,4-di[(1-benzimidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=11.436(4)
b=5.640(2)
c=26.449(9)
α= 90.00
β= 99.252(5)
γ= 90.00
V = 1683.7(10)
4504814(4-bromo-phenylacetonitrile oxime)2, 1,4-di[(1-imidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=12.9436(5)
b=5.1863(2)
c=21.6419(9)
α= 90.00
β= 93.4500(10)
γ= 90.00
V = 1450.17(10)
4504815(4-bromo-PhC(CN)(=NOH))2, 1,4-di[(2-methyl-1-benzimidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=7.4360(9)
b=19.613(2)
c=12.5107(15)
α= 90.00
β= 107.063(2)
γ= 90.00
V = 1744.3(3)
4504816(4-bromo-PhC(CN)(=NOH))2, 1,4-di[(2-methyl-1-imidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=7.0034(8)
b=10.6013(12)
c=11.1605(12)
α= 77.000(2)
β= 75.995(2)
γ= 84.920(2)
V = 782.87(15)
4504817(3-chloro-phenylacetonitrile oxime)2, 1,4-di[(1-imidazolyl)methyl]benzene
Crystal Growth & Design (2006) 6, 4 1033
a=5.9000(10)
b=7.2231(12)
c=17.088(3)
α= 86.114(3)
β= 89.633(4)
γ= 73.472(3)
V = 696.5(2)
45048181,4-[bis(2-methylbenzimidazol-1-yl)methyl]benzene, (4-bromobenzacetoxime)2
Crystal Growth & Design (2006) 6, 4 1033
a=10.9286(11)
b=14.1612(15)
c=11.3704(12)
α= 90.00
β= 92.619(2)
γ= 90.00
V = 1757.9(3)
45048603-[(benzimidazol-1-yl)methyl]benzamide
Crystal Growth & Design (2005) 5, 3 1283
a=9.2133(11)
b=11.6848(13)
c=12.1071(15)
α= 104.058(9)
β= 98.623(8)
γ= 94.900(7)
V = 1239.9(3)
45048623-[(2-chlorobenzimidazol-1-yl)methyl]-benzamide
Crystal Growth & Design (2005) 5, 3 1283
a=8.8067(7)
b=11.8803(12)
c=14.0856(15)
α= 74.800(4)
β= 72.485(5)
γ= 68.786(4)
V = 1290.5(2)
45048643-[(benzimidazol-1-yl)methyl]benzamide, 4-nitrobenzoic acid
Crystal Growth & Design (2005) 5, 3 1283
a=7.5178(9)
b=9.1850(11)
c=15.0850(15)
α= 105.516(6)
β= 100.600(7)
γ= 100.339(8)
V = 957.4(2)
45048653-[(2-methylbenzimidazol-1-yl)methyl]PhCOOH,(4-NO2PhCOOH)2
Crystal Growth & Design (2005) 5, 3 1283
a=7.5292(5)
b=11.0980(8)
c=17.2512(11)
α= 81.865(4)
β= 77.854(3)
γ= 74.581(4)
V = 1352.89(16)
4506067SVP-4N-AA (4-pyridyl)-CONH-(2-pyridyl), HOOC-(CH2)4-COOH
Crystal Growth & Design (2012) 12, 5 2579
a=11.9508(11)
b=19.8752(19)
c=7.3996(8)
α= 90.00
β= 105.384(4)
γ= 90.00
V = 1694.6(3)
4506070SVP-4N-SUC (4-pyridyl)-CONH-(2-pyridyl), HOOC-(CH2)2-COOH
Crystal Growth & Design (2012) 12, 5 2579
a=11.2578(7)
b=19.6623(11)
c=19.8130(12)
α= 93.236(3)
β= 91.236(3)
γ= 90.298(3)
V = 4377.6(5)
4506075SVP-3N-PA (3-pyridyl)-CONH-(2-pyridyl), HOOC-(CH2)5-COOH
Crystal Growth & Design (2012) 12, 5 2579
a=7.5711(5)
b=11.9820(8)
c=20.1758(13)
α= 82.560(4)
β= 80.081(4)
γ= 85.195(4)
V = 1784.2(2)
4507105EH-4-97-4 4-Br-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=7.6597(9)
b=13.4779(16)
c=13.7575(16)
α= 117.048(4)
β= 90.413(5)
γ= 90.972(4)
V = 1264.6(3)
4507106EH-1-25-05 4-CN-PhCOOH, 4-I-pyrazole
Crystal Growth & Design (2012) 12, 11 5806
a=6.7767(5)
b=8.0047(6)
c=11.1806(10)
α= 83.315(4)
β= 77.745(4)
γ= 85.862(4)
V = 587.94(8)
4507107EH-01-25-06 3,5-(NO2)2-PhCOOH, 4-I-pyrazole
Crystal Growth & Design (2012) 12, 11 5806
a=10.1937(6)
b=11.2088(6)
c=13.1357(7)
α= 111.112(2)
β= 108.116(2)
γ= 92.381(2)
V = 1310.62(13)
4507108EH-6-65-12 3,5-Me2-4-Cl-pyrazole, 3-MeO-4-HO-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=12.8138(7)
b=7.2047(4)
c=15.2522(9)
α= 90.00
β= 90.00
γ= 90.00
V = 1408.08(14)
4507109EH-6-65-11 3,5-Me2-4-Cl-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=6.4021(4)
b=7.8731(5)
c=28.0067(19)
α= 90.00
β= 90.195(3)
γ= 90.00
V = 1411.65(16)
4507110EH-4-45-3 3,5-Me2-4-Br-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=6.4192(7)
b=8.0239(8)
c=28.206(3)
α= 90.00
β= 90.00
γ= 90.00
V = 1452.8(3)
4507111EH-6-65-6 (3,5-Me2-4-Cl-pyrazole)2, 2,4-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=9.3369(18)
b=10.489(2)
c=11.923(2)
α= 77.852(12)
β= 75.218(11)
γ= 68.606(12)
V = 1042.3(3)
4507112EH-6-65-23 3,5-Me2-4-I-pyrazole, 3,5-(NO2)2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=7.1993(5)
b=7.8251(6)
c=13.4055(10)
α= 93.999(3)
β= 90.564(3)
γ= 96.990(3)
V = 747.64(10)
4507113EH-4-90-1 pyrazole, 3,5-Cl2-PhCOOH
Crystal Growth & Design (2012) 12, 11 5806
a=7.7111(12)
b=9.6247(14)
c=14.275(2)
α= 73.355(8)
β= 89.353(9)
γ= 68.778(7)
V = 941.1(2)
4507114EH-3-93-7 pyrazole, [(NO2)2-PhCOOH]2
Crystal Growth & Design (2012) 12, 11 5806
a=7.1717(6)
b=13.2773(12)
c=20.7542(16)
α= 90.00
β= 92.463(4)
γ= 90.00
V = 1974.4(3)
4507115EH-3-94-1 3,5-Me2-pyrazole, 3,5-dinitrobenzoic acid hydrate
Crystal Growth & Design (2012) 12, 11 5806
a=8.6114(4)
b=6.2504(3)
c=27.4741(13)
α= 90.00
β= 94.822(3)
γ= 90.00
V = 1473.55(12)
4508292PC-4-43-6 1-bromo-4-iodotetrafluorobenzene, (2,3,5,6-tetramethylpyrazine)2
Crystal Growth & Design (2013) 13, 9 4145
a=7.0820(4)
b=9.4394(5)
c=9.9426(6)
α= 70.354(2)
β= 69.519(2)
γ= 83.639(2)
V = 586.38(6)
4508293PC-4-45-6 1-I-4-(4-Br-F4-phenyl)-F4-benzene, 2,3,5,6-Me4-pyridine
Crystal Growth & Design (2013) 13, 9 4145
a=13.6678(7)
b=13.8355(8)
c=11.3735(6)
α= 90.00
β= 104.064(2)
γ= 90.00
V = 2086.3(2)
4508294J3 1-bromo-4-iodotetrafluorobenzene, 2,3,5,6-Me4-pyridine-1-oxide
Crystal Growth & Design (2013) 13, 9 4145
a=14.121(6)
b=4.3893(17)
c=14.377(6)
α= 90.00
β= 109.448(6)
γ= 90.00
V = 840.3(6)
4508295J1 1-bromo-4-iodotetrafluorobenzene, 4,4-bipyridyl-1-oxide
Crystal Growth & Design (2013) 13, 9 4145
a=4.0681(3)
b=13.2198(9)
c=16.4160(11)
α= 107.014(4)
β= 91.675(3)
γ= 98.090(4)
V = 833.49(10)
4508296PC-4-45-11 1-I-4-(4-Br-F4-phenyl)-F4-benzene, 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole
Crystal Growth & Design (2013) 13, 9 4145
a=9.1185(7)
b=10.8775(9)
c=13.8025(11)
α= 80.633(3)
β= 71.005(3)
γ= 83.608(4)
V = 1274.71(18)
4508297PC-4-45-2 1-iodo-4-(4-bromotetrafluorophenyl)-tetrafluorobenzene, 4-(dimethylamino)pyridine
Crystal Growth & Design (2013) 13, 9 4145
a=7.7850(5)
b=11.3455(7)
c=12.8117(9)
α= 114.949(3)
β= 95.310(3)
γ= 90.597(3)
V = 1020.06(12)
4508298PC-4-45-3 1-iodo-4-(4-bromotetrafluorophenyl)-tetrafluorobenzene, 4-(1-pyrrolidinyl)-pyridine
Crystal Growth & Design (2013) 13, 9 4145
a=13.3208(8)
b=23.8060(14)
c=7.8323(4)
α= 90.00
β= 123.017(3)
γ= 90.00
V = 2082.6(2)
4508299PC-3-86a N-(4-I-phenyl)-4-Br-F4-benzamide
Crystal Growth & Design (2013) 13, 9 4145
a=7.1847(7)
b=25.234(3)
c=8.0401(8)
α= 90.00
β= 107.157(5)
γ= 90.00
V = 1392.8(3)
4508300PC-4-55-8 (4-Br-F4-phenyl)-4-I-F4-benzamide, 1,2-bis(4-pyridyl)ethylene
Crystal Growth & Design (2013) 13, 9 4145
a=4.6568(3)
b=11.0639(6)
c=12.2258(7)
α= 98.373(2)
β= 100.443(2)
γ= 97.995(2)
V = 603.94(6)
4508301PC-4-55-5 (4-Br-F4-phenyl)-4-I-F4-benzamide, 1,2-bis(4-pyridyl)ethane
Crystal Growth & Design (2013) 13, 9 4145
a=15.2758(8)
b=7.9588(4)
c=20.3245(10)
α= 90.00
β= 99.899(2)
γ= 90.00
V = 2434.2(2)
4508302PC-4-55-6 (4-Br-F4-phenyl)-4-I-F4-benzamide, 4,4-bipyridyl
Crystal Growth & Design (2013) 13, 9 4145
a=4.7774(7)
b=7.9111(10)
c=25.928(4)
α= 89.199(8)
β= 85.294(9)
γ= 75.073(8)
V = 943.6(2)
70052792,2-bis(benzanthracenol imine)binaphthyl, dichloromethane
Dalton transactions (Cambridge, England : 2003) (2007) 15 1520-1527
a=8.8321(14)
b=11.5748(18)
c=42.316(7)
α= 90.00
β= 90.00
γ= 90.00
V = 4326.0(12)
7005280(2,2-bis(benzanthracenol imine)binaphthyl Zn(ii))2 (CH2CL2)2 (Et2O)
Dalton transactions (Cambridge, England : 2003) (2007) 15 1520-1527
a=12.5693(17)
b=32.926(4)
c=12.6967(17)
α= 90.00
β= 119.512(2)
γ= 90.00
V = 4572.8(10)
7005281(2,2-bis(benzanthracenol imine)binaphthyl Fe(ii)) (Et2O)
Dalton transactions (Cambridge, England : 2003) (2007) 15 1520-1527
a=12.6954(3)
b=12.6954(3)
c=24.3493(10)
α= 90.00
β= 90.00
γ= 120.00
V = 3398.68(18)
70061591,2-bis(benzoquinoline imine) cyclohexane
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=6.6519(2)
b=6.6519(2)
c=56.855(3)
α= 90.00
β= 90.00
γ= 90.00
V = 2515.71(17)
7006160bis(benzoquinoline imine)cyclohexane ZnCl2 (dichloromethane)2
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=15.0432(14)
b=17.1668(17)
c=15.9752(14)
α= 90.00
β= 111.564(4)
γ= 90.00
V = 3836.7(6)
7006161AL-3-163
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=17.5549(10)
b=11.7013(7)
c=17.5582(11)
α= 90.00
β= 116.636(3)
γ= 90.00
V = 3223.9(3)
7006162AL-3-190 cyclohexanediamine bis(8-iPr-quinoline-1-CHO imine)
Dalton transactions (Cambridge, England : 2003) (2007) 42 4788-4796
a=13.045(3)
b=13.450(3)
c=14.109(3)
α= 116.747(14)
β= 91.053(12)
γ= 115.182(15)
V = 1931.9(9)
7006759bis(2-amino-4-(3-pyridyl)-6-methylpyrimidine) mu- (OAc)4dicopper(ii)
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.0282(5)
b=10.6399(7)
c=18.9041(13)
α= 90.00
β= 99.3600(10)
γ= 90.00
V = 1593.27(18)
7006760bis(2-amino-4-(3-pyridyl)-6-methoxypyrimidine) mu-(OAc)4 dicopper(ii)
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.2800(6)
b=9.3983(6)
c=11.2233(7)
α= 71.144(4)
β= 81.585(4)
γ= 79.240(4)
V = 808.49(10)
7006761(2-amino-4-(3-pyridyl)-6-methoxypyridine)2, (2- fluorobenzoate)4 Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=10.1310(9)
b=10.5499(8)
c=12.2936(9)
α= 64.853(5)
β= 86.149(5)
γ= 67.896(4)
V = 1095.24(16)
7006762(2-amino-4-(3-pyridyl)-6-methylpyridine)2, (2FPhCOO)4 Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=21.3553(18)
b=17.9389(15)
c=11.4887(9)
α= 90.00
β= 90.742(5)
γ= 90.00
V = 4400.8(6)